Tag: NOAC

Pooled analysis shows LAAC is cheaper than drug therapy for AF

A pooled analysis of five-year data from the PROTECT AF and PREVAIL trials has shown left atrial appendage closure (LAAC) to be cost‐effective, and...
Cardiac Rhythm news for specialists

Eliminate AF shows low thromboembolic and bleeding events with edoxaban

Uninterrupted anticoagulation with edoxaban (Lixiana, Daiichi Sankyo) resulted in low rates of thromboembolic and bleeding events in patients with atrial fibrillation undergoing catheter ablation,...

Less bleeding in ablation with interrupted dabigatran compared to uninterrupted warfarin 

The results of ABRIDGE-J, a Japanese multicentre randomised study on minimally interrupted dabigatran vs. uninterrupted warfarin for catheter ablation, were presented during a late-breaking...

Risk of dementia higher without oral anticoagulants for AF

A retrospective national Swedish registry study by Leif Friberg and Mårten Rosenqvist (Karolinska Institutet, Stockholm, Sweden) has found that the risk of dementia is...

Dabigatran consistently shown to decrease risk of brain bleeds compared to...

A new comparative study between dabigatran and warfarin finds similar ischemic stroke risks, but fewer brain bleeds for dabigatron compared with warfarin in US-based...
rivaroxaban

Rivaroxaban significantly reduces the risk of major amputation by 70% in...

Rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily also significantly (p=0.0003) reduces the risk of the composite outcome of...

Low-risk AF for stroke identified with CHA2DS2-VASc Score

A Korean nationwide cohort study by Tae-Hoon Kim et al has shown that truly low-risk Asian patients with atrial fibrillation (AF) for stroke can...

ESC 2016: Edoxaban is safe and effective in AF patients undergoing...

ENSURE-AF, the largest prospective, randomised clinical trial to date of anticoagulation for electrical cardioversion in non-valvular atrial fibrillation, has shown that edoxaban is an...

Results of phase 3b ENSURE-AF study investigating edoxaban in AF patients...

Daiichi Sankyo has announced it will present the first results from ENSURE-AF, the largest prospective randomised clinical trial to date evaluating a non-vitamin K...
Cardiac Rhythm news for specialists

Bristol-Myers Squibb and Pfizer to present new apixaban analyses at ESC

Bristol-Myers Squibb and Pfizer have announced that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) on apixaban (Eliquis) will be presented at the European...